Research Paper Volume 15, Issue 20 pp 11554—11570
Comprehensive analysis of transcriptome data and experimental identification show that solute carrier 35 member A2 (SLC35A2) is a prognostic marker of colorectal cancer
Figure 4. The relationship of SLC35A2 expression and clinical features in patients with colorectal cancer. (A) The expression of SLC35A2 in colorectal carcinoma was higher than that of normal tissues. (B) SLC35A2 expression was higher in Stages III and IV than in Stages I and II. (C) The difference of SLC35A2 expression between N0 and N1 was statistically significant (p < 0.05). (D–G) The expression level of SLC35A2 in different sexes, age, M and T stages was not statistically significant (p > 0.05). (H) The diagnostic value of SLC35A2 in CRC was assessed by drawing ROC and PRC curves. The AUC of the ROC curve is 0.834 and the PRC curve is 0.984 (*p < 0.05, **p < 0.01, ***p < 0.001, ns means p > 0.05). (I) Representative images of IHC staining of SLC35A2 in normal colon tissue (left) and colorectal cancer tissue (right) was presented.